Search research articles
Contact Us
Filters
Showing results (91-100 of 156) with videos related to
Page
of 16
Sort By:
Frontiers in Aging Neuroscience
|
December 16, 2022
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks
Yuting Zhang, Upamanyu Ghose, Noel J Buckley, et al.
Journal of Alzheimer'S Disease : JAD
|
September 24, 2016
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization
Piotr Lewczuk, Natalia Lelental, Ingolf Lachmann, et al.
Alzheimer'S Research & Therapy
|
June 19, 2017
One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
Loïc Dayon, Seu Ping Guiraud, John Corthésy, et al.
Neuro-Degenerative Diseases
|
April 13, 2025
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland
Ansgar Felbecker, Olivier Rouaud, Aurelien Lathuiliere, et al.
Praxis
|
October 27, 2021
[Recommendations for the Diagnosis and Therapy of Psychotic Disorders in the Elderly]
Stefan Klöppel, Egemen Savaskan, Jean-Marie Annoni, et al.
The Lancet. Neurology
|
February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel, Axel Rominger, Peter Bartenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Cerebrospinal fluid proteome alterations related to depressive symptoms in cognitive decline and Alzheimer's disease
Miriam Rabl, Willem L Hartog, Wiesje M van der Flier, et al.
Journal of Alzheimer'S Disease : JAD
|
July 24, 2009
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form
Hans-Wolfgang Klafki, Piotr Lewczuk, Heike Kamrowski-Kruck, et al.
Alzheimer'S Research & Therapy
|
May 29, 2020
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease
Elles Konijnenberg, Betty M Tijms, Johan Gobom, et al.
Proteomes
|
August 27, 2021
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
Betty Marije Tijms, Johan Gobom, Charlotte Teunissen, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 156) with videos related to
Sort By:
Page
of 16
Frontiers in Aging Neuroscience
|
December 16, 2022
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks
Yuting Zhang, Upamanyu Ghose, Noel J Buckley, et al.
Journal of Alzheimer'S Disease : JAD
|
September 24, 2016
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization
Piotr Lewczuk, Natalia Lelental, Ingolf Lachmann, et al.
Alzheimer'S Research & Therapy
|
June 19, 2017
One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
Loïc Dayon, Seu Ping Guiraud, John Corthésy, et al.
Neuro-Degenerative Diseases
|
April 13, 2025
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland
Ansgar Felbecker, Olivier Rouaud, Aurelien Lathuiliere, et al.
Praxis
|
October 27, 2021
[Recommendations for the Diagnosis and Therapy of Psychotic Disorders in the Elderly]
Stefan Klöppel, Egemen Savaskan, Jean-Marie Annoni, et al.
The Lancet. Neurology
|
February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel, Axel Rominger, Peter Bartenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Cerebrospinal fluid proteome alterations related to depressive symptoms in cognitive decline and Alzheimer's disease
Miriam Rabl, Willem L Hartog, Wiesje M van der Flier, et al.
Journal of Alzheimer'S Disease : JAD
|
July 24, 2009
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form
Hans-Wolfgang Klafki, Piotr Lewczuk, Heike Kamrowski-Kruck, et al.
Alzheimer'S Research & Therapy
|
May 29, 2020
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease
Elles Konijnenberg, Betty M Tijms, Johan Gobom, et al.
Proteomes
|
August 27, 2021
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
Betty Marije Tijms, Johan Gobom, Charlotte Teunissen, et al.
Page
of 16